Top Markets
#1 DogBull DogBull +104.66%
#2 Siacoin Siacoin +47.15%
#3 ADO Protocol ADO Protocol +45.80%
#4 UnifAI Network UnifAI Network +44.45%
#5 MarsCoin MarsCoin +43.18%
#6 Magma Finance Magma Finance +28.28%
#7 Useless Coin Useless Coin +25.17%
#8 Ontology Gas Ontology Gas +19.44%
#9 Arowana Arowana +18.05%
#10 Nockchain Nockchain +17.11%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Rank in Stocks #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Share Price
$3.12
Market Cap
$294.21M
Change (1 day)
-3.26%
Change (1 year)
-51.10%
Country
US
Trade Myriad Genetics, Inc. (MYGN)

Category

Healthcare
Operating Margin for Myriad Genetics, Inc. (MYGN)
Operating Margin as of 2026 TTM: 0.00%
According to Myriad Genetics, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Myriad Genetics, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
17.69% -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
20.42% -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
0.00% -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
-10.70% -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
32.03% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.